Study of a Digital Treatment Tool Combined With Obesity Medications in Adolescents Aged 12 to 17 Years with Obesity

What this Trial Is About

Researchers are evaluating whether adding a digital-physical treatment tool called Evira to obesity medications can improve treatment outcomes in adolescents with obesity. The study focuses on patients aged 12 to 17 years and aims to compare the combined approach of medication plus Evira with medication alone. Obesity medications liraglutide and semaglutide have shown some effects in this age group, but long-term success is limited, prompting the need for optimized treatment strategies. This randomized controlled trial assigns participants to one of two groups one receiving liraglutide or semaglutide with the Evira digital tool, and the other receiving medication alone with standard clinic support. The Evira tool includes a digitless scale used daily at home, linked to a mobile app that tracks weight trends using BMI standard deviation scores and allows communication between families and healthcare professionals. The study follows participants for six months to assess outcomes. Participants will undergo physical exams, provide background information, and complete electronic questionnaires. Researchers will monitor changes in BMI SDS from treatment start to six months, along with treatment adherence, side effects, and perceptions of the digital tool by both patients and professionals. Quality of life assessments will also be collected. The study is conducted across multiple centers in Sweden and sponsored by Karolinska Institutet.

The Evira Study: Additional Support During Obesity Treatment